Form 8-K - Current report:
SEC Accession No. 0001193125-26-023387
Filing Date
2026-01-27
Accepted
2026-01-27 08:19:16
Documents
14
Period of Report
2026-01-27
Items
Item 7.01: Regulation FD Disclosure
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d29201d8k.htm   iXBRL 8-K 33690
2 EX-99.1 d29201dex991.htm EX-99.1 15473
6 GRAPHIC g29201dsp4.jpg GRAPHIC 13198
  Complete submission text file 0001193125-26-023387.txt   189175

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA ntla-20260127.xsd EX-101.SCH 2846
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE ntla-20260127_lab.xml EX-101.LAB 17993
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE ntla-20260127_pre.xml EX-101.PRE 11258
16 EXTRACTED XBRL INSTANCE DOCUMENT d29201d8k_htm.xml XML 3630
Mailing Address 40 ERIE STREET SUITE 130 CAMBRIDGE MA 02139
Business Address 40 ERIE STREET SUITE 130 CAMBRIDGE MA 02139 857-285-6200
Intellia Therapeutics, Inc. (Filer) CIK: 0001652130 (see all company filings)

EIN.: 364785571 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37766 | Film No.: 26562095
SIC: 2835 In Vitro & In Vivo Diagnostic Substances
(CF Office: 03 Life Sciences)